© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 24, 1853-1856,
December 18, 1996
© 1996 Oxford University Press
Glutathione S-Transferase and N-Acetyltransferase Genotypes and Asbestos-Associated Pulmonary Disorders
Department of Industrial Hygiene and Toxicology, Helsinki University Central Hospital Finland
Uusimaa Regional Institute, Finnish Institute of Occupational Health, Helsinki University Central Hospital, Finland Helsinki, Finland
Department of Internal Medicine, Helsinki University Central Hospital Finland
Correspondence to: Ari Hirvonen, Ph.D., Department of Industrial Hygiene and Toxicology, Molecular Epidemiology Group, Finnish Institute of Occupational Health, FIN-00250 Helsinki, Finland.
BACKGROUND: Humans vary in their ability to metabolize endogenous and exogenous compounds. Glutathione S-transferases (GSTs) and N-acetyltrans-ferases(NATs) are enzymes involved in the detoxification of hazardous agents. The GSTM1 and GSTT1 genes exhibit null (i.e., deletion) polymorphisms; in specific individuals, homozygous deletion (i.e., both copies lost) of these genes can be detected. Polymorphism of the NAT2 gene results in slow and fast acetylators of potentially toxic substances. The GSTM1-null and the NAT2 slow-acetylator genotypes have been associated with increased risks for the development of environmentally induced cancers.
PURPOSE: We assessed whether homozygous GSTM1-null or GSTT1-null genotypes or the NAT2 slow-acetylator genotype were associated with increased risks for the development of malignant and non-malignant asbestos-related pulmonary disorders in a cohort of Finnish construction workers.
METHODS: The study population consisted of 145 asbestos insulators who were classified as having been exposed to high levels of asbestos; 69 of these individuals had no pulmonary disorders (control subjects), and 76 had either malignant mesothelioma (n= 24) or nonmalignant pulmonary disorders, such as asbestosis and/or pleural plaques (n = 52). Lymphocyte DNA and the polymerase chain reaction were used to determine the GSTM1, GSTT1, and NAT2 genotypes of the study subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) estimating the relative risks of disease associated with specific genotypes were calculated from 2 x 2 tables by use of Fisher's exact method. Results: Risks for the development of asbestos-related pulmonary disorders were not affected significantly by homozygous deletion of the GSTM1 or GSTT1 genes. However, the risk of developing both malignant and non-malignant pulmonary disorders for individuals with a NAT2 slow-acetylator genotype was more than twice that observed for those with a NAT2 fast-acetylator genotype (OR = 2.3; 95% CI = 1.1–4.7); the risk of developing malignant mesothelioma for NAT2 slow acetylators was increased almost fourfold (OR = 3.8; 95% CI = 1.2–14.3). Individuals who lacked the GSTM1 gene and possessed a NAT2 slow-acetylator genotype had a risk of developing malignant and nonmalignant pulmonary disorders that was approximately fivefold greater than that observed for those who had the GSTM1 gene and a NAT2 fast-acetylator genotype (OR = 5.1; 95% CI = 1.6–17.6); these individuals had a fourfold increased risk of developing nonmalignant pulmonary disorders (OR = 4.1; 95% CI = 1.1–17.2) and an eightfold increased risk of developing malignant mesothelioma (OR = 7.8; 95% CI % 1.4–78.7) when compared with the same reference group.
CONCLUSIONS: Individuals with homozygous deletion of the GSTM1 gene and a NAT2 slow-acetylator genotype who are exposed to high levels of asbestos appear to have enhanced susceptibility to asbestos-related pulmonary disorders. [J Natl Cancer Inst 1996; 88: 1853–6]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Gates, S. S. Tworoger, K. L. Terry, L. Titus-Ernstoff, B. Rosner, I. De Vivo, D. W. Cramer, and S. E. Hankinson Talc Use, Variants of the GSTM1, GSTT1, and NAT2 Genes, and Risk of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2436 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sabbioni, C. R. Jones, O. Sepai, A. Hirvonen, H. Norppa, H. Jarventaus, H. Glatt, D. Pomplun, H. Yan, L. R. Brooks, et al. Biomarkers of exposure, effect, and susceptibility in workers exposed to nitrotoluenes. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 559 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bolognesi, F. Martini, M. Tognon, R. Filiberti, M. Neri, E. Perrone, E. Landini, P. A. Canessa, G. P. Ivaldi, P. Betta, et al. A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1741 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kettunen, A.G. Nicholson, B. Nagy, H. Wikman, J.K. Seppanen, T. Stjernvall, T. Ollikainen, V. Kinnula, S. Nordling, J. Hollmen, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray Carcinogenesis, January 1, 2005; 26(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pavanello, P. Simioli, S. Lupi, P. Gregorio, and E. Clonfero Exposure Levels and Cytochrome P450 1A2 Activity, but not N-Acetyltransferase, Glutathione S-Transferase (GST) M1 and T1, Influence Urinary Mutagen Excretion in Smokers Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 998 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tuimala, G. Szekely, S. Gundy, A. Hirvonen, and H. Norppa Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity Carcinogenesis, June 1, 2002; 23(6): 1003 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Marczynski, H.-P. Rihs, B. Rossbach, J. Holzer, J. Angerer, M. Scherenberg, G. Hoffmann, T. Bruning, and M. Wilhelm Analysis of 8-oxo-7,8-dihydro-2'-deoxyguanosine and DNA strand breaks in white blood cells of occupationally exposed workers: comparison with ambient monitoring, urinary metabolites and enzyme polymorphisms Carcinogenesis, February 1, 2002; 23(2): 273 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Stucker, P. Boffetta, S. Antilla, S. Benhamou, A. Hirvonen, S. London, and E. Taioli Lack of Interaction between Asbestos Exposure and Glutathione S-Transferase M1 and T1 Genotypes in Lung Carcinogenesis Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen Glutathione S-Transferase M1, M3, P1, and T1 Genetic Polymorphisms and Susceptibility to Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 229 - 236. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Laffon, E. Pasaro, and J. Mendez Effects of styrene-7,8-oxide over p53, p21, bcl-2 and bax expression in human lymphocyte cultures Mutagenesis, March 1, 2001; 16(2): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Hou, S. Fält, K. Yang, F. Nyberg, G. Pershagen, K. Hemminki, and B. Lambert Differential Interactions between GSTM1 and NAT2 Genotypes on Aromatic DNA Adduct Level and HPRT Mutant Frequency in Lung Cancer Patients and Population Controls Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 133 - 140. [Abstract] [Full Text]
|
|
|
|
|
|
M. Krajinovic, C. Richer, H. Sinnett, D. Labuda, and D. Sinnett Genetic Polymorphisms of N-Acetyltransferases 1 and 2 and Gene-Gene Interaction in the Susceptibility to Childhood Acute Lymphoblastic Leukemia Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 557 - 562. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. S. Beckett Occupational Respiratory Diseases N. Engl. J. Med., February 10, 2000; 342(6): 406 - 413. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
S.-M. Hou, D. Ryberg, S. Falt, A. Deverill, T. Tefre, A.-L. Borresen, A. Haugen, and B. Lambert GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients Carcinogenesis, January 1, 2000; 21(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jourenkova-Mironova, A. Voho, C. Bouchardy, H. Wikman, P. Dayer, S. Benhamou, and A. Hirvonen Glutathione S-Transferase GSTM3 and GSTP1 Genotypes and Larynx Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 185 - 188. [Abstract] [Full Text]
|
|